Physician profile
Glory John
NPI 1467983460
$16,356.96
in general payments reported to CMS, 2019-2025
25 companies · $3,481 in 2025
The $3,481 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,438 · 2022: $2,501 · 2023: $2,977 · 2024: $4,960 · 2025: $3,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Travel and Lodging: $1,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,148.75 |
| Travel and Lodging | $1,269.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,577.40 | 2021-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $2,500.78 | 2021-2025 | |
| Ucb, INC. | $1,911.62 | 2021-2025 | Cimzia, Bimzelx |
| Modernatx, INC. | $1,605.82 | 2024 | |
| Pfizer INC. | $1,382.19 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,085.09 | 2021-2025 | |
| Lilly USA, LLC | $775.44 | 2021-2024 | Taltz |
| Mallinckrodt Hospital Products INC. | $700.99 | 2021-2025 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $696.62 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $524.28 | 2021-2025 | Benlysta, Nucala |
| Janssen Biotech, INC. | $508.98 | 2021-2025 | Tremfya, Remicade, Stelara |
| Horizon Therapeutics Plc | $409.45 | 2021-2023 | Krystexxa |
| Radius Health, INC. | $382.70 | 2021-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $284.83 | 2021-2025 | Orencia |
| Aurinia Pharma U.S., INC. | $204.00 | 2021-2025 | Lupkynis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $149.56 | 2023-2024 | Hyrimoz |
| Fresenius Kabi USA, LLC | $129.31 | 2023-2025 | Idacio, Tyenne |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.44 | 2021-2025 | Cyltezo, Jascayd |
| Alexion Pharmaceuticals, INC. | $117.99 | 2023-2025 | Strensiq |
| Genzyme Corporation | $97.69 | 2021-2025 | |
| Sobi, INC | $91.72 | 2021-2025 | |
| Organon LLC | $40.07 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $25.00 | 2022 | |
| Genentech USA, INC. | $17.18 | 2025 | Actemra |
| Antares Pharma, INC. | $15.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glory John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.